Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

44 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Transcriptomic and Protein Expression Analysis Reveals Clinicopathological Significance of Bloom Syndrome Helicase (BLM) in Breast Cancer.
Arora A, Abdel-Fatah TM, Agarwal D, Doherty R, Moseley PM, Aleskandarany MA, Green AR, Ball G, Alshareeda AT, Rakha EA, Chan SY, Ellis IO, Madhusudan S. Arora A, et al. Among authors: moseley pm. Mol Cancer Ther. 2015 Apr;14(4):1057-65. doi: 10.1158/1535-7163.MCT-14-0939. Epub 2015 Feb 11. Mol Cancer Ther. 2015. PMID: 25673821
Clinicopathological significance of ATM-Chk2 expression in sporadic breast cancers: a comprehensive analysis in large cohorts.
Abdel-Fatah TM, Arora A, Alsubhi N, Agarwal D, Moseley PM, Perry C, Doherty R, Chan SY, Green AR, Rakha E, Ball G, Ellis IO, Madhusudan S. Abdel-Fatah TM, et al. Among authors: moseley pm. Neoplasia. 2014 Nov 20;16(11):982-91. doi: 10.1016/j.neo.2014.09.009. eCollection 2014 Nov. Neoplasia. 2014. PMID: 25425972 Free PMC article.
Untangling the ATR-CHEK1 network for prognostication, prediction and therapeutic target validation in breast cancer.
Abdel-Fatah TM, Middleton FK, Arora A, Agarwal D, Chen T, Moseley PM, Perry C, Doherty R, Chan S, Green AR, Rakha E, Ball G, Ellis IO, Curtin NJ, Madhusudan S. Abdel-Fatah TM, et al. Among authors: moseley pm. Mol Oncol. 2015 Mar;9(3):569-85. doi: 10.1016/j.molonc.2014.10.013. Epub 2014 Nov 6. Mol Oncol. 2015. PMID: 25468710 Free PMC article.
Nottingham Clinico-Pathological Response Index (NPRI) after neoadjuvant chemotherapy (Neo-ACT) accurately predicts clinical outcome in locally advanced breast cancer.
Abdel-Fatah TM, Ball G, Lee AH, Pinder S, MacMilan RD, Cornford E, Moseley PM, Silverman R, Price J, Latham B, Palmer D, Chan A, Ellis IO, Chan SY. Abdel-Fatah TM, et al. Among authors: moseley pm. Clin Cancer Res. 2015 Mar 1;21(5):1052-62. doi: 10.1158/1078-0432.CCR-14-0685. Epub 2014 Dec 17. Clin Cancer Res. 2015. PMID: 25520390
Chk1 phosphorylated at serine345 is a predictor of early local recurrence and radio-resistance in breast cancer.
Alsubhi N, Middleton F, Abdel-Fatah TM, Stephens P, Doherty R, Arora A, Moseley PM, Chan SY, Aleskandarany MA, Green AR, Rakha EA, Ellis IO, Martin SG, Curtin NJ, Madhusudan S. Alsubhi N, et al. Among authors: moseley pm. Mol Oncol. 2016 Feb;10(2):213-23. doi: 10.1016/j.molonc.2015.09.009. Epub 2015 Oct 3. Mol Oncol. 2016. PMID: 26459098 Free PMC article.
Clinicopathological and prognostic significance of RECQL5 helicase expression in breast cancers.
Arora A, Abdel-Fatah TM, Agarwal D, Doherty R, Croteau DL, Moseley PM, Hameed K, Green A, Aleskandarany MA, Rakha EA, Patterson K, Ball G, Chan SY, Ellis IO, Bohr VA, Bryant HE, Madhusudan S. Arora A, et al. Among authors: moseley pm. Carcinogenesis. 2016 Jan;37(1):63-71. doi: 10.1093/carcin/bgv163. Epub 2015 Nov 19. Carcinogenesis. 2016. PMID: 26586793 Free PMC article.
SPAG5 as a prognostic biomarker and chemotherapy sensitivity predictor in breast cancer: a retrospective, integrated genomic, transcriptomic, and protein analysis.
Abdel-Fatah TMA, Agarwal D, Liu DX, Russell R, Rueda OM, Liu K, Xu B, Moseley PM, Green AR, Pockley AG, Rees RC, Caldas C, Ellis IO, Ball GR, Chan SYT. Abdel-Fatah TMA, et al. Among authors: moseley pm. Lancet Oncol. 2016 Jul;17(7):1004-1018. doi: 10.1016/S1470-2045(16)00174-1. Epub 2016 Jun 14. Lancet Oncol. 2016. PMID: 27312051 Clinical Trial.
Evaluation of CDK12 Protein Expression as a Potential Novel Biomarker for DNA Damage Response-Targeted Therapies in Breast Cancer.
Naidoo K, Wai PT, Maguire SL, Daley F, Haider S, Kriplani D, Campbell J, Mirza H, Grigoriadis A, Tutt A, Moseley PM, Abdel-Fatah TMA, Chan SYT, Madhusudan S, Rhaka EA, Ellis IO, Lord CJ, Yuan Y, Green AR, Natrajan R. Naidoo K, et al. Among authors: moseley pm. Mol Cancer Ther. 2018 Jan;17(1):306-315. doi: 10.1158/1535-7163.MCT-17-0760. Epub 2017 Nov 13. Mol Cancer Ther. 2018. PMID: 29133620 Free PMC article.
SHON expression predicts response and relapse risk of breast cancer patients after anthracycline-based combination chemotherapy or tamoxifen treatment.
Abdel-Fatah TMA, Broom RJ, Lu J, Moseley PM, Huang B, Li L, Liu S, Chen L, Ma RZ, Cao W, Wang X, Li Y, Perry JK, Aleskandarany M, Nolan CC, Rakha EA, Lobie PE, Chan SYT, Ellis IO, Hwang LA, Lane DP, Green AR, Liu DX. Abdel-Fatah TMA, et al. Among authors: moseley pm. Br J Cancer. 2019 Apr;120(7):728-745. doi: 10.1038/s41416-019-0405-x. Epub 2019 Feb 28. Br J Cancer. 2019. PMID: 30816325 Free PMC article.
44 results